Announcement Regarding Acquisition of Olympus RMS Corporation's Stock (Transfer Agreement)
Mar 23, 2021
ROHTO Pharmaceutical Co., Ltd. (President : Masashi Sugimoto, hereinafter "ROHTO Pharmaceutical"), with the aim of expanding its business in the field of regenerative medicine, has resolved to acquire all the shares of Olympus RMS Corporation (President and CEO: Masahiko Hamano, hereinafter "Olympus RMS"). We are pleased to announce that the transfer procedures have been completed as of today..
Reason for Stock Acquisition
Olympus RMS was founded in December 2008 and has been primarily engaged in research and development of treatment methods using autologous cultured chondrocyte transplantation. Currently, clinical trials using the CCI (Cultured Chondrocyte Implantation) kit developed by the company have been underway since November 2018, targeting cartilage defects in knee joints. This CCI kit aims to achieve minimally invasive treatment by using a tissue adhesive (fibrin glue).
This stock acquisition is aimed at adding the orthopedic surgery field to our portfolio of regenerative medical products and accelerating the establishment of regenerative medicine as a future pillar of our business. Furthermore, we expect synergies in the R&D field between Olympus RMS and our cell manufacturing technology, leading to reduced cell manufacturing costs and the creation of new, unique pipelines. We are committed to delivering excellent regenerative medical products to patients and healthcare professionals as quickly as possible, contributing to the field of healthcare.
Overview of Olympus RMS Corporation
| (1) Company name |
Olympus RMS Corporation |
| (2) Address |
4th Floor, NTB Hachioji Building, 3-1-7 Myojincho, Hachioji City, Tokyo 192-0046 |
| (3) Business Activities |
- Research and development of treatment methods using autologous cultured chondrocyte transplantation
- Research and development of novel regenerative medical technologies and evaluation techniques
|
| (4) Representative |
Representative Director, Masahiko Hamano |
| (5) Established |
December 2008 |
| (6) Number of employees |
337 ※Including contract and dispatched employees (as of March 1, 2021) |
Overview of the Company after Stock Acquisition
| (1) Company name |
Interstem Co., Ltd. |
| (2) Adress |
4th Floor, NTB Hachioji Building, 3-1-7 Myojincho, Hachioji City, Tokyo 192-0046 |
| (3) Business Activities |
same as above |
| (4) Representative |
President and CEO, Nobuhiro Yamamoto |
Future Outlook
The impact on our consolidated performance for the fiscal year ending March 2021 is minimal, and we will promptly inform you if there are any matters that need to be disclosed in the future.